Metabolic idiosyncratic DILI of ritonavir and hepatotoxicity (NASH) of glucocorticoids could be exacerbated by their interactions with pharmaco-immunomodulatory agents (DDIs) via PXR activation. The gene discussed is NR1I2; the disease is metabolic dysfunction-associated steatohepatitis.